Sick with "Shareholder Value"

Reducing prices for key prescription drugs in the United States is always a challenge. But fresh analysis from the New Institute for Economic Thinking finds that the status quo will remain largely intact unless pharmaceutical companies sever executive pay from stock price performance and the companies are banned from stock buybacks, among other reforms. We speak with William Lazonick, professor emeritus of economics at the University of Massachusetts and co-founder and president of the Academic-Industry Research Network. Read more https://www.ineteconomics.org/perspectives/blog/sick-with-shareholder-value-us-pharmas-financialized-business-model-during-the-pandemic

Become a supporter of this podcast: https://www.spreaker.com/podcast/facepalm-america--5189985/support.